Erudio Healtherudio.com
Drug
Giredestrant trials: what clinicians said in public
An HCP commentary report on 1 clinical trial studying giredestrant: MORPHEUS-panBC. It covers what clinicians said in public about one trial, on podcasts, videos and posts, every statement linked to its source. Below them, 3 more trials with public commentary and no report yet.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| MORPHEUS-panBC NCT03424005 · Hoffmann-La Roche | metastatic breast cancer | Phase 1/Phase 2 | 7 | 4 | Focused | Nov 20, 2026 | Preview |
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| evERA NCT05306340 · Genentech, Inc. DeepView → | ER-positive, HER2-negative locally advanced or metastatic breast cancer | Phase 3 | Deep | View | |||
| persevERA NCT04546009 · Hoffmann-La Roche DeepView → | Not given | Phase 3 | Deep | View | |||
| PREcoopERA NCT05896566 · ETOP IBCSG Partners Foundation DeepView → | premenopausal ER-positive/HER2-negative early breast cancer | Phase 2 | Deep | View | |||